David Johnston Net Worth

The estimated Net Worth of David Michael Johnston is at least $6.2 million dollars as of 17 March 2021. Mr. Johnston owns over 21,598 units of PPD Inc stock worth over $2,695,196 and over the last 5 years he sold PPD stock worth over $3,500,752. In addition, he makes $0 as Executive Vice President - Global Clinical Development at PPD Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Johnston PPD stock SEC Form 4 insiders trading

David has made over 3 trades of the PPD Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 21,598 units of PPD stock worth $228,723 on 17 March 2021.

The largest trade he's ever made was selling 60,894 units of PPD Inc stock on 1 March 2021 worth over $2,176,352. On average, David trades about 17,499 units every 25 days since 2020. As of 17 March 2021 he still owns at least 57,005 units of PPD Inc stock.

You can see the complete history of Mr. Johnston stock trades at the bottom of the page.

David Johnston biography

David Johnston serves as Executive Vice President - Global Clinical Development of the Company. From July 2013 to September 2016, Mr. Johnston served as executive vice president and global head of PPD Laboratories. Prior to joining the Company, Mr. Johnston worked at Laboratory Corp of America (LH) from April 1998 to June 2013, where he served as senior vice president and global head of the clinical trials business.

How old is David Johnston?

David Johnston is 51, he's been the Executive Vice President - Global Clinical Development of PPD Inc since 2016. There are 7 older and 11 younger executives at PPD Inc. The oldest executive at PPD Inc is Jeffrey Kindler, 64, who is the Independent Director.

What's David Johnston's mailing address?

David's mailing address filed with the SEC is C/O PPD, INC., 929 NORTH FRONT STREET, WILMINGTON, NC, 28401.

Insiders trading at PPD Inc

Over the last 22 years, insiders at PPD Inc have traded over $14,532,346,241 worth of PPD Inc stock and bought 130,455 units worth $3,520,800 . The most active insiders traders include Corporate Investors Viii, L..., Corporate Investors Vii, Lt... et Group Management L.L.C.Carl.... On average, PPD Inc executives and independent directors trade stock every 53 days with the average trade being worth of $124,899,671. The most recent stock trade was executed by Corporate Investors Viii, L... on 8 December 2021, trading 132,841,266 units of PPD stock currently worth $6,309,960,135.

What does PPD Inc do?

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Company's customers include pharmaceutical, biotechnology, medical device, academic and government organization s. With offices in 46 countries and more than 26,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health.

Complete history of Mr. Johnston stock trades at PPD Inc

PPD Inc executives and stock owners

PPD Inc executives and other stock owners filed with the SEC include:

• David Simmons,
  Chairman of the Board, Chief Executive Officer
• William Sharbaugh,
  Chief Operating Officer
• Christopher Scully,
  Chief Financial Officer, Executive Vice President, Treasurer, Assistant Secretary
• Anshul Thakral,
  Executive Vice President, Chief Commercial Officer
• B. Judd Hartman,
  Executive Vice President, Chief Administrative Officer, General Counsel
• Jeffrey Kindler,
  Independent Director
• Colin Hill,
  Independent Director
• Maria Hilado,
  Independent Director
• Tracy Krumme,
  Vice President, Head of Investor Relations
• Stephen Wise,
  Independent Director
• Allen Thorpe,
  Independent Director
• P. Hunter Philbrick,
  Independent Director
• Stephen Ensley,
  Independent Director
• Joe Bress,
  Independent Director
• Glen Donovan,
  Chief Accounting Officer
• Roger Smith,
  Senior Vice President and General Manager of AES
• Karen Kaucic,
  Executive Vice President and President of Evidera, Chief Medical Officer
• David Johnston,
  Executive Vice President - Global Clinical Development
• Christopher Fikry,
  Executive Vice President - Global Laboratory Services
• Ronald Garrow,
  Chief Human Resource Officer, Executive Vice President
• Group Inc.Carlyle Group Man...,
  
• Group Management L.L.C.Carl...,
  
• Jill Pellegrino,
  SVP & General Manager of AES
• Peter Grunebaum,
  Director
• Cecil Mark Brown,
  Sr. VP & CEO
• Charlie Stephen Williamson,
  Chief Financial Officer
• Kathleen Susan Pinson,
  Vice President
• Randy Harp,
  Chief Operating Officer
• Harland Cecil Stonecipher,
  Founder, Chairman of the Board
• Martin H Belsky,
  Director
• John W Hail,
  Director
• Steven Riley Hague,
  Director
• Paid Legal Services Inc Pre,
  Director
• Judd Hartman,
  See Remarks
• Thomas W Smith,
  10% owner
• Corporate Investors Viii, L...,
  
• Julia James,
  EVP, General Counsel,Secretary